As part of its advocacy program in the United States, ACRO submits regulatory comments to U.S. regulators. This comment letter, submitted by ACRO to the FDA in 2025 on the Innovative Design CGT guidelines on the Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations, can be found below.